Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The finding of isolated hepatitis B core antibody (isolated HBc) in absent of recent active hepatitis could cause by several scenarios, including false positive, remote infection without viremia, and occult infection with low viremia. Hepatitis B virus (HBV) vaccine booster could be a great prevention strategy for those who do not have HBV viremia. There is no standard consensus for management of this issue especially among HIV infected population. In addition, prior studies revealed that HIV-infected individuals had lower immunologic response to HBV vaccine than general population. This study intends to compare the immune response and safety of 4- versus 3-standard dose of hepatitis B virus vaccination in HIV-infected adults who has isolated HBc. The immunologic response will be evaluated after the participants receive vaccination.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 3-standard dose HBV vaccination group | Active Comparator | participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months |
|
| 4-standard dose HBV vaccination group | Active Comparator | participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hepatitis B vaccine | Biological | Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Immunologic response to 4 versus 3 doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody, demonstrated by percentage of responders (with anti-HBs Ab ≥ 10 mIU/mL ) at week 28 | Immunologic response to 4 versus 3 doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody, demonstrated by percentage of responders (with anti-HBs Ab ≥ 10 mIU/mL ) at week 28 | 28 weeks after the first dose of HBV vaccination |
| Measure | Description | Time Frame |
|---|---|---|
| Anamnestic response at week 4 | Anamnestic response at week 4 | 4 weeks after the first dose of HBV vaccination |
| Percentage of responders (with anti-HBs Ab ≥ 10 mIU/mL) at month 12 | Percentage of responders (with anti-HBs Ab ≥ 10 mIU/mL) at month 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Romanee Chaiwarith, MD | Contact | +66-5393-6457 | rchaiwar@gmail.com | |
| Quanhathai Kaewpoowat, MD | Contact | +66-5393-6457 | quanhathai@rihes.org |
| Name | Affiliation | Role |
|---|---|---|
| Romanee Chaiwarith, MD | Chiang Mai University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maharaj Nakorn Chiang Mai Hospital, Department of medicine, Chiang Mai University | Recruiting | Muang, Chiang Mai | Chiang Mai | 50200 | Thailand |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31053142 | Derived | Laksananun N, Praparattanapan J, Kotarathititum W, Supparatpinyo K, Chaiwarith R. Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody. AIDS Res Ther. 2019 May 3;16(1):10. doi: 10.1186/s12981-019-0225-3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017325 | Hepatitis B Vaccines |
| ID | Term |
|---|---|
| D014761 | Viral Hepatitis Vaccines |
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
Not provided
Not provided
Open-label, randomized controlled trial (RCT) with 1:1 allocation in parallel arms
Not provided
Not provided
No masking
Not provided
| 12 months after the first dose of HBV vaccination |
| Percentage of high-level responders (with anti-HBs Ab ≥ 100 mIU/mL) at week 28 and month 12 | Percentage of high-level responders (with anti-HBs Ab ≥ 100 mIU/mL) at week 28 and month 12 | 28 weeks and 12 months after the first dose of HBV vaccination |
| Intensity and frequency of vaccine adverse event (AE) | Intensity and frequency of vaccine adverse event (AE) | 1 year |
| Geometric mean titers of anti-HBs Ab at week 28 and month 12 | Geometric mean titers of anti-HBs Ab at week 28 and month 12 | 28 weeks and 12 months after the first dose of HBV vaccination |
| Predictive factors associated with response to vaccine (age, sex, CD4 count) | Predictive factors associated with response to vaccine (age, sex, CD4 count) | 1 year |
| D045424 |
| Complex Mixtures |